Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of NEU-AX would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2005) — listing | $406,718 12.6× | $589,125 12.6× |
| Year 6 (2010) | $297,042 11.9× | $430,510 12.0× |
| Year 11 (2015) | $107,564 6.2× | $154,720 6.2× |
| Year 16 (2020) | $39,218 4.0× | $56,282 4.0× |
| Year 21 (2025) | $2,138 1.0× | $3,089 1.0× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
Auckland, New Zealand
Popular scenarios with NEU
For illustration only — not investment advice. Past performance is not indicative of future results.